Pair Name	Lycorine, Bortezomib
Disease Info	[ICD-11: 2A83]	Multiple myeloma		Investigative
Biological Phenomena	Inhibition-->Autophagy
Gene Regulation	Down-regulation	Phosphorylation	BCL2	hsa596
	Down-regulation	Expression	BECN1	hsa8678
	Down-regulation	Expression	HMGB1	hsa3146
	Down-regulation	Expression	MAP1LC3B	hsa81631
	Down-regulation	Phosphorylation	MAP2K7	hsa5609
	Down-regulation	Phosphorylation	MAPK1	hsa5594
In Vitro Model	ARH-77	Plasma cell myeloma	Homo sapiens (Human)	CVCL_1072
	MM1.S	Plasma cell myeloma	Homo sapiens (Human)	CVCL_8792
	NCI-H929	Plasma cell myeloma	Homo sapiens (Human)	CVCL_1600
In Vivo Model	The mice were subcutaneously inoculated in the flank with 5×10⁶ MM.1S cells in 100 µl of phosphate-buffered saline.
Result	We observed higher HMGB1 expression in bortezomib resistant cells and the combination of bortezomib plus lycorine was highly efficient in vitro and in vivo myeloma models as well as in re-sensitizing resistant cells to bortezomib. These observations indicate lycorine as an effective autophagy inhibitor and reveal that lycorine alone or in combination with bortezomib is a potential therapeutic strategy.